Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025
Vaxart (OTCQX: VXRT) will present clinical updates on its oral norovirus and COVID-19 pill vaccine programs at World Vaccine Congress Europe 2025 in Amsterdam on October 13–16, 2025. Two presentations by Dr. Sean Tucker will cover a bivalent oral norovirus vaccine with recent immunogenicity improvements and a clinical update on the oral COVID-19 vaccine covering Phase 1 to Phase 2 data.
The company highlights that its oral recombinant pill platform has generated both systemic and mucosal immune responses and shown a favorable safety and tolerability profile in clinical trials, positioning these programs as ongoing clinical-stage efforts toward potential global public-health solutions.
Vaxart (OTCQX: VXRT) parteciperà a World Vaccine Congress Europe 2025 ad Amsterdam dal 13 al 16 ottobre 2025 per fornire aggiornamenti clinici sui suoi programmi di vaccino orale contro il norovirus e contro COVID-19 sotto forma di pillola. Due presentazioni del Dr. Sean Tucker copriranno un vaccino norovirus orale bivalente con recenti miglioramenti dell'immunogenicità e un aggiornamento clinico sul vaccino orale contro COVID-19 che includerà dati dalla fase 1 alla fase 2.
L'azienda evidenzia che la sua piattaforma di pillola ricombinante orale ha prodotto risposte immunitarie sia sistemiche che mucosali e ha mostrato un profilo di sicurezza e tollerabilità favorevole negli studi clinici, posizionando questi programmi come sforzi clinici in corso verso potenziali soluzioni di salute pubblica globale.
Vaxart (OTCQX: VXRT) presentará actualizaciones clínicas sobre sus programas de vacuna en forma de píldora oral contra el norovirus y contra COVID-19 en el World Vaccine Congress Europe 2025 en Amsterdam del 13 al 16 de octubre de 2025. Dos presentaciones del Dr. Sean Tucker cubrirán una vacuna oral bivalente contra el norovirus con mejoras recientes de inmunogenicidad y una actualización clínica de la vacuna oral contra COVID-19 que abarcará datos de las fases 1 a 2.
La empresa destaca que su plataforma de píldora recombinante oral ha generado respuestas inmunes sistémicas y mucosas y ha mostrado un perfil de seguridad y tolerabilidad favorable en ensayos clínicos, posicionando estos programas como esfuerzos clínicos en curso hacia posibles soluciones de salud pública global.
Vaxart (OTCQX: VXRT)는 World Vaccine Congress Europe 2025가 암스테르담에서 열리는 기간 동안 경구 노로바이러스와 COVID-19 알약 백신 프로그램에 대한 임상 업데이트를 발표할 예정입니다. 2025년 10월 13–16일에 두 차례의 발표에서 최근 면역원성 개선이 이뤄진 이중 노로바이러스 구강 백신과 1상에서 2상까지의 데이터를 다루는 경구 COVID-19 백신에 대한 임상 업데이트를 다룰 것입니다.
회사는 자사의 경구 재조합 알약 플랫폼이 전신 면역 반응과 점막 면역 반응을 모두 생성했고 임상 시험에서 안전성 및 내약성 프로파일이 우수하다고 강조하며, 이러한 프로그램을 전 세계 공중 보건 솔루션 가능성에 대한 잠재적 솔루션으로 나아가는 진행 중인 임상 단계의 노력으로 제시합니다.
Vaxart (OTCQX: VXRT) présentera des mises à jour cliniques sur ses programmes de vaccins oraux sous forme de pilule contre le norovirus et la COVID-19 lors du World Vaccine Congress Europe 2025 à Amsterdam du 13 au 16 octobre 2025. Deux présentations du Dr Sean Tucker couvriront un vaccin oral norovirus bivalent avec des améliorations récentes de l'immunogénicité et une mise à jour clinique sur le vaccin oral COVID-19 couvrant les données de la phase 1 à la phase 2.
L'entreprise souligne que sa plateforme de pilule recombinant orale a généré des réponses immunitaires systémiques et muqueuses et a démontré un profil de sécurité et de tolérabilité favorable dans les essais cliniques, positionnant ces programmes comme des efforts cliniques en cours vers d'éventuelles solutions de santé publique mondiale.
Vaxart (OTCQX: VXRT) wird klinische Updates zu seinen oralen Norovirus- und COVID-19-Pillenimpfstoffprogrammen beim World Vaccine Congress Europe 2025 in Amsterdam vom 13. bis 16. Oktober 2025 präsentieren. Zwei Präsentationen von Dr. Sean Tucker werden einen zweibändigen oralen Norovirus-Impfstoff mit jüngsten Immunogenitätsverbesserungen und ein klinisches Update zum oralen COVID-19-Impfstoff abdecken, das Daten von Phase 1 bis Phase 2 umfasst.
Das Unternehmen hebt hervor, dass seine orale rekombinante Pillenplattform sowohl systemische als auch mukosale Immunantworten erzeugt hat und in klinischen Studien ein vorteilhaftes Sicherheits- und Verträglichkeitsprofil gezeigt hat, wodurch diese Programme als laufende klinische Entwicklungen zu potenziellen globalen Lösungen für die öffentliche Gesundheit positioniert werden.
Vaxart (OTCQX: VXRT) ستقدم تحديثات سريرية حول برامجها للقاح فموي مضاد للنوروفيروس ولقاح COVID-19 على شكل حبوب في World Vaccine Congress Europe 2025 في أمستردام في الفترة من 13 إلى 16 أكتوبر 2025. ستغطي عرضان للمرض Sean Tucker لقاحًا فمويًا ثنائي النمط ضد النوروفيروس مع تحسينات مناعية حديثة وتحديثًا سريريًا عن لقاح COVID-19 الفموي يغطي بيانات المرحلة 1 إلى المرحلة 2.
وتبرز الشركة أن منصة الحبوب الفموية المتمثلة في لقاح مُعاد التركيب قد أنتجت استجابات مناعية جهازية ومخاطية وأظهرت ملف سلامة وتحمل مفضل في التجارب السريرية، مما يمكّن هذه البرامج من أن تكون جهودًا في المرحلة السريرية قيد التنفيذ نحو حلول صحية عامة عالمية.
Vaxart (OTCQX: VXRT) 将在 Amsterdam 的 World Vaccine Congress Europe 2025 上就其口服诺如病毒和 COVID-19 口服疫苗计划提供临床更新，时间为 2025 年 10 月 13–16 日。Dr. Sean Tucker 的两场演讲将介绍一种双价口服诺如病毒疫苗及其最近的免疫原性改进，以及覆盖从 I 期到 II 期数据的口服 COVID-19 疫苗的临床更新。
公司强调，其口服重组药丸平台已产生全身性和黏膜免疫应答，并在临床试验中显示出有利的安全性和耐受性特征，将这些计划定位为朝全球公共卫生解决方案潜在方向的正在进行中的临床阶段努力。
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that it will present research highlighting its advances in its norovirus and COVID-19 programs at the World Vaccine Congress Europe 2025 taking place in Amsterdam on October 13-16, 2025.
Vaxart’s mission is to improve global public health by developing a transformative oral pill vaccine platform. With multiple promising clinical-stage programs, including those targeting norovirus and COVID-19, the Company is committed in solving serious health challenges facing society. Vaxart’s differentiated platform has generated both systemic and mucosal immune responses and demonstrated a favorable safety and tolerability profile in clinical trials, reinforcing its potential of bringing worldwide game changing solutions.
Presentation Information:
Title: Oral bivalent vaccine for norovirus protection. Recent improvements to improve immunogenicity and potentially efficacy
Speaker: Dr. Sean Tucker, Founder and Chief Scientific Officer
Date: Wednesday, October 15
Time: 11:45 a.m. CEST
Location: Track 1
Title: Oral Covid Vaccine - Clinical update from phase 1 to phase 2B
Speaker: Dr. Sean Tucker, Founder and Chief Scientific Officer
Date: Wednesday, October 15
Time: 3:45 p.m. CEST
Location: Track 5
About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
Note Regarding Forward-Looking Statements
This communication contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are subject to the “safe harbor” created by those sections, concerning our business, operations, and financial performance and condition as well as our plans, objectives, and expectations for business operations, funding, and financial performance and condition. Any statements contained herein that are not of historical facts may be deemed to be forward-looking statements. You can identify these statements by words such as “anticipate,” “assume,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “should,” “will,” “would,” and other similar expressions that are predictions of or indicate future events and future trends. These forward-looking statements are based on current expectations, estimates, forecasts, and projections about our business and the industry in which we operate and management’s beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties, and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this communication may turn out to be inaccurate. Factors that could materially affect our business operations and financial performance and condition include, but are not limited to, those risks and uncertainties described under “Item 1A - Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024 and risk factors disclosed in any subsequent Quarterly Reports on Form 10-Q. You are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are based on information available to us as of the date of this communication. Unless required by law, we do not intend to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise. You should, however, review the factors and risks we describe in the reports we will file from time to time with the SEC after the date of this communication.
Contact
Vaxart Media and Investor Relations
Matt Steinberg
FINN Partners
IR@vaxart.com
(646) 871-8481
FAQ
When will Vaxart (VXRT) present its norovirus and COVID-19 vaccine updates at World Vaccine Congress Europe 2025?
What topics will Vaxart (VXRT) cover in its October 15, 2025 presentations?
Who is presenting Vaxart's (VXRT) research at the World Vaccine Congress Europe 2025?
Where and how can investors attend Vaxart's (VXRT) presentations on October 15, 2025?
What clinical evidence does Vaxart (VXRT) cite about its oral vaccine platform?
